前列腺癌组织中TRAIL受体的表达及意义  

Expression of TRAIL receptors in human prostate cancer and its significance

作　　者：谢礼仁 潘卫兵[1] 曾灿[1] 朱斌[1] 周建华[2] 

机构地区：[1]深圳市坪山新区人民医院泌尿外科,广东深圳518118 [2]深圳市龙岗区人民医院泌尿外科,广东深圳518172

出　　处：《海南医学》2014年第15期2191-2192,共2页Hainan Medical Journal

基　　金：深圳市龙岗区2013年度科技计划项目(编号:YS2013024)

摘　　要：目的探讨前列腺癌组织中TRAIL受体的表达及意义。方法采用免疫组织化学方法检测45例前列腺癌组织及15例良性前列腺增生组织中DR4、DR5及DcR1受体的表达水平。结果高分化、中分化、低分化前列腺癌组织与前列腺增生组织比较DR4、DR5受体的表达水平差异均无统计学意义(P>0.05),但高分化、中分化、低分化前列腺癌组织中DcR1的表达水平均明显低于前列腺增生组织,其差异均有统计学意义(P<0.05),且DcR1的表达水平在高分化、中分化、低分化前列腺癌组织中依次降低,差异有统计学意义(P<0.05)。结论 TRAIL受体DcR1在前列腺癌的发生发展中可能发挥重要作用。Objective To investigate the expression of TRAIL receptors in human prostate cancer and its clinical significance. Methods Immunohistochemistry was used to detect the expression levels of DR4, DR5 and DcR1 receptors in 45 cases of prostate cancer and 15 cases of benign prostatic hyperplasia. Results There were no significant differences in the expression levels of DR4 and DR5 receptor in well-differentiated, moderately differentiated, poorly differentiated prostate cancer and benign prostatic hyperplasia （P〉0.05）. However, the expression levels of DcR1 in well-moderately differentiated, poorly differentiated prostate cancer tissue were significantly lower than that in benign prostatic hyperplasia （P〈0.05）. And the expression levels of DcR1 in well-differentiated, moderately differentiated, poorly differentiated prostate cancer tissues were gradually reduced （P〈0.05）. Conclusion TRAIL recep-tors DcR1 may play an important role in the development of prostate cancer.

关 键 词：前列腺癌 细胞凋亡 免疫组织化学 肿瘤坏死因子相关凋亡诱导配体 受体 

分 类 号：R737.25[医药卫生—肿瘤]